Europe Robot Assisted PCI Market By Products (Robotic Systems, Instruments, Accessories), End User (Hospitals, Cath Labs), Country (France, Italy, Rest of Europe) – Industry Trends and Forecast to 2026
Robotic assisted PCI system helps for minimally invasive treatment of coronary artery disease (CAD). It gives lesser pain to patients for the treatment of coronary artery disease (CAD). Percutaneous coronary intervention (PCI) is treated by robotic assistance, in this surgeon operates via joysticks and touchscreen to control the physician movement.
Firstly the PCI procedure was performed in Zurich, in September 1977, by Andreas Gruentzig, a Swiss radiologist. In 1977, PCI procedure was known as percutaneous transluminal coronary angioplasty. In the early phase this procedure gets less success due to risks associated with the use of large guide catheters that could easily rupture the vessel and large balloon catheters with low burst pressure points. In 1986, this technology gets improved and used in most of the coronary interventions. Currently this PCI technology is known as percutaneous coronary intervention and nowadays the procedure of percutaneous coronary intervention (PCI) is operated by robotic assisted system, the robotic surgical system is the latest development in minimally invasive medical technology.
Europe robot assisted PCI market is projected to register a healthy CAGR in the forecast period of 2019 to 2026.
Segmentation: Europe Robot Assisted PCI Market
Europe robot assisted PCI market is segmented into two notable segments which are products and end user.
- On the basis of products, the market is segmented into robotic systems, instruments, and accessories.
- On the basis of end user, the market is segmented into hospitals, cath labs.
Competitive Analysis: Europe Robot Assisted PCI Market
Some of the major players operating in this market are Corindus, Inc., Robocath
- In February 2019, Robocath announced that their product R-one robotic device got CE certification in the field of interventional cardiology. After getting CE certification, company could begin commercialization in Europe and the Middle East. It is the first European robotic solution to get the CE certification in the field of interventional cardiology.
- In May 2019, Corindus, Inc. announced that they have shown their product CorPath GRX System at EuroPCR in Paris and France. CorPath GRX System is an only product approved by the U.S. Food and Drug Administration (FDA) and has CE marked robotic platform for percutaneous coronary intervention (PCI). After showcasing this product in EuroPCR, the company enhances their market presence in Europe region.
Research Methodology: Europe Robot Assisted PCI Market
Key Opinion Leaders (KOL’s): Doctors, Healthcare Professionals, Researchers, Distributors, and Industrialists.
Industry Participants: CEO’s, V.P.’s, Marketing/Product Managers, Market Intelligence Managers and, National Sales Managers.